|
|||||
|
|
Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects |
|
| Authors: | R. H. A. Becker J. Stechl J. Msihid C. Kapitza |
| Affiliation: | 1. Sanofi‐Aventis Deutschland GmbH, , Frankfurt am Main, Germany;2. Sanofi, , Paris, France;3. PROFIL, , Neuss, Germany |
| Abstract: | |
| Keywords: | healthy subjects insulin response lixisenatide pharmacodynamics pharmacokinetics type 2 diabetes mellitus |